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This paper describes the heterogeneous clinical phenotype of a cohort
of nine patients diagnosed with heterozygous mutations in STAT1. We
report data of extended immunophenotyping over time and we show
lung damage in four patients. The increased phosphorylation of STAT1
in response to IFNγ and IFNα stimulation proves the gain-of-function
nature of the defects. The data are supplemental to our original article
concurrently published “Clinical heterogeneity of dominant chronic
mucocutaneous candidiasis disease: presenting as treatment-resistant
candidiasis and chronic lung disease” [1], where additional results and
interpretation of our research can be found.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
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Value of the data
 The data provide novel clinical and immunological phenotypes of the emerging highly hetero-
geneous primary immunodeﬁciency due to heterozygous mutations of STAT1.
 The data of the increased STAT1 phosphorylation in response to IFNs conﬁrm the gain-of-function
as the pathogenetic mechanism of dominant mutations in STAT1.
 The data of immunophenotyping may stimulate further research on the molecular pathways
leading to lymphopenia and highlight the clinical utility of monitoring of lymphocyte subsets as
prognostic marker.1. Data
We describe in details the clinical phenotype of a cohort of nine pediatric or adult patients whomainly
presented with chronic mucocutaneous candidiasis disease (CMCD) and were consequently screened for
STAT1mutations [1]. After identiﬁcation of heterozygous defects, the gain-of-function nature of the STAT1
variants was demonstrated by prolonged phosphorylation of STAT1 with exaggerated signaling through
IFNγ and IFNα pathways for both previously reported (Fig. S1) [2–4] and for novel variants [1]. The
heterogeneous clinical phenotype was analyzed in term of severity of CMCD, type of infections, auto-
immune manifestations, detailed immunophenotyping over time (as detailed in Table S1), and long-term
complications, particularly developing of chronic lung disease (as illustrated in Fig. S2).2. Experimental design, materials and methods
2.1. Clinical survey
Medical history and clinical data were compiled retrospectively and prospectively from medical
records of all patients of our cohort. Patients who were treated primarily at the Departments of
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puted tomography imaging to stage lung disease. Extended immunophenotyping was performed. All
patients or their guardians provided written informed consent under approved protocols of their
center of reference. All patients were Caucasian and their clinical phenotype is herein detailed.
2.1.1. Patient 1
The patient is a 11-year-old boy born to nonconsanguineous parents. At the age of 1 year he began
to experience recurrent oral thrush. He once developed skin candidiasis (forehead), and since the age
of 8 years he has persistent onychomycosis of his second hand ﬁnger. Oropharyngeal and skin can-
didiasis responded ﬁrst to oral ﬂuconazole, but requiring oral itraconazole (100 mg/die) following
resistance. Nail infection never responded to these medications. Since early infancy he suffered from
recurrent upper respiratory tract infections, he had one episode of right pneumonia at the age of
5 years, and several bouts of obstructive bronchitis. At the age of 6.5 years blood tests revealed
increased TSH (7.155 mU/L, range 0.27–4.2), and he was commenced on levothyroxine at the age of
9 years (following increase of TSH to 61.63 mU/L). Thyroid antibodies tested negative, but thyroid
ultrasound showed dishomogeneous appearance of the gland with hypoechoic areas. His immuno-
logical assessment revealed low IgM (31 mg/dl, range449) on repeated determinations since the age
of 6 years.
2.1.2. Patient 2
Mother of patient 1, this 45-year-old woman presented, since early childhood, with severe oro-
pharyngeal and nails chronic candidiasis, resistant to oral antifungal treatment (ﬁrst ﬂuconazole and
voriconazole, then itraconazole progressively increased from 100 to 400 mg/die). Since her adolescent
age, she suffered from oesophageal candidiasis, requiring intravenous antifungal treatment (caspo-
fungin). She suffered from recurrent skin boils, and she experienced episodes of recurrent fever
associated to weight loss. She had bouts of pulmonary infections and a chest computed tomography
(CT)-scan performed when she was 21 year-old showed bronchiectasis in the left lower lobe and the
lingula (Fig. S2). She developed recurrent infection with Pseudomonas aeruginosa at the age of 31 year-
old, causing higher frequency of pulmonary exacerbations. She had gestational diabetes, but never
developed autoimmune manifestations. In her adulthood, she developed persistent T and B cells
lymphopenia (Table S1), with unprotective antibody response to vaccine (anti-tetanus toxoid anti-
body 0.02 UI/ml).
2.1.3. Patient 3
A 33-year-old man was born to nonconsanguineous parents. He presented with recurrent oral
thrush since the age of 6 months, well responding to oral treatment (ﬁrst ﬂuconazole then itraco-
nazole, progressively increased from 100 to 200 mg/die). He was diagnosed with oesophageal can-
didiasis at the age of 19 years, well responding to intravenous treatment (amphotericin B). Since
childhood, he had repeated episodes of otitis media and multiple bouts of pneumonia. Bronchiectasis
were ﬁrstly documented at the age of 10 years in the left lower lobe and the lingua (Fig. S2). He also
suffered from recurrent skin boils. At the age of 15 years he presented with multiple granulomatous
necrotizing lymphadenitis caused by Cryptococcus neoformans infection, which responded to intra-
venous ﬂuconazole. At the age of 28 years he developed visceral leishmaniasis, was treated with
intravenous amphotericin B, but, because of drug-related nephropathy, was replaced with miltefo-
sine. He also had recurrent molluscum and Human Papilloma Virus (HPV) (warts) infections. He
developed hypothyroidism at the age of 32 years (TSH4100 mU/L), associated to negative thyroid
antibodies, and was started on daily levothyroxine. On autoimmunity screening, he has positive
antinuclear antibodies (title 1:320) and positive anti-double stranded DNA antibody (138–122%,
normal value o35%), clinically associated to systemic lupus erythematosus (SLE)-like facial skin
lesions. Immunological investigations detected poor vaccine response to tetanus toxoid (0.07 UI/ml),
associated to persistent T cells lymphopenia and NK cells defect by his adult age (Table S1).
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A 15-year-old boy was born at term to nonconsanguineous parents. Since childhood, he presented
with recurrent respiratory tract infections complicated with chronic sinusitis. At the age of 5 years he
ﬁrst had oral thrush secondary to antibiotic therapy, and since then oral candidiasis occurred when
on antibiotics, easily responding to topical antifungal (miconazole). At the age of 14 years he devel-
oped bone marrow aplasia requiring platelets and blood transfusions, likely cotrimoxazole-related, as
he had been started on antibiotic prophylaxis for respiratory infections. On that occasion, a chest CT-
scan was done, revealing bronchiectasis and thickening of bronchial walls bilaterally in the lower
lobes and the lingua, and the right middle lobe (Fig. S2). During the following year, he experienced
two pulmonary exacerbations caused by Serratia marcescens, and one due to Pseudomonas aeruginosa,
the latter eradicated following oral ciproﬂoxacin treatment. He has vitiligo and positive antinuclear
antibodies (title 1:320). He has poor antibody response (anti-tetanus toxoid antibody 0.03 UI/ml); a
determination of low CD4þT cells was detected once (Table S1).
2.1.5. Patient 5
A 10-year-old boy was born at term to nonconsanguineous parents. From 2 months of age he had
chronic oral thrush and suffered from gastroesophageal reﬂux. At the age of 4 months he had one
episode of severe bilateral pneumonia with Pneumocystis jirovecii (PCC), complicated by Streptococcus
viridans and Candida albicans sepsis. Lymphopenia was detected in his ﬁrst year of life (Table S1). He
subsequently suffered from multiple bouts of pneumonia, but he is currently free of bronchiectasis.
When he was 4-year-old an endoscopy showed esophageal Candida infection, and he was treated
with intravenous voriconazole with transitory beneﬁt. A severe gastroesophageal reﬂux disease led to
a Nissen fundoplication at the age of 5 years. Unfortunately he had a fundoplication leak with sec-
ondary hiatal hernia and poor feeding, and Candida infection recurred. He responded to oral itraco-
nazole (200 mg/die). He presents short stature, but growth hormone deﬁciency was ruled out.
2.1.6. Patient 6
A 7-year-old girl was born at term to nonconsanguineous parents. She presented with chronic
candidiasis of oral mucosa, head skin, and hand nails from the age of 2 years, responding to oral
treatment (ﬂuconazole 50 mg/die). She had several episodes of respiratory tract infections, including
pneumonia with Pseudomonas aeruginosa. A CT-scan at the age of 6 years showed bronchiectasis in
the right middle lobe and the lingula (Fig. S2). She has microcytic anemia and was started with iron
therapy.
2.1.7. Patient 7
A 14-year-old girl was born at term to nonconsanguineous parents. Since the age of 6 months she
suffered from vaginal candidiasis, responding to topical antifungal treatment, and recurrent oro-
pharyngeal candidiasis (treated with ﬂuconazole from 100 to 200 mg/die). She also suffered from
chronic sinusitis and one episode of pneumonia was recorded at the age of 11 years.
2.1.8. Patient 8
A 17-year-old boy was born preterm (36 weeks) to nonconsanguineous parents. Since he was 7
year-old he presented with recurrent oropharyngeal and nails candidiasis, followed by onset of
oesophageal localization in his adolescent age, well responding to oral ﬂuconazole. At the age of
8 years he suffered from severe chicken pox, and since he was 11 year-old he experienced recurrent
herpetic infections involving genitals and limbs, recurrent S. aureus skin abscesses and suppurative
eyelid infections. He also developed parodontitis.
2.1.9. Patient 9
A 8-year-old girl was born at term to nonconsanguineous parents. She presented with recurrent
oral thrush since the age of 5 months, associated with oesophageal Candida colonization, and fol-
lowed by nail candidiasis by 1 year of age. Mucocutaneous candidiasis responded to oral ﬂuconazole.
She had one episode of lobar pneumonia at the age of 7 months and recurrent upper respiratory tract
infections. Since she was 2 year-old she suffered from recurrent infections with Herpes Simplex Virus
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(TSH 100 mU/L, but negative thyroid auto-antibodies) at the age of 7 years, and was started on daily
levothyroxine treatment.
2.2. Flow cytometry
Written informed consent was obtained from patients or parents (for minors) and healthy control
to collect blood for in vitro functional studies. Peripheral blood from both patients and healthy donors
was left unstimulated and stimulated with IFNγ (1000 U/ml), or IFNα (40,000 U/ml), for 30 min. Cells
were lysed, permeabilized, and stained, as indicated by the manufacturer (BD Phosﬂow). Speciﬁc
phycoerythrin-labeled antibody for phosphorylated STAT1 (pSTAT1) (pY701; BD Biosciences) was
then used, and pSTAT1 was evaluated in both lymphocyte and monocyte gates. Cells were acquired
using FACSCalibur (BD Bioscence) and analyzed by FlowJo version 7.5 Software (TreeStar).
2.3. Statistical analysis
Statistical analyses were performed using GraphPad Prism Version 5.0 (GraphPad Software, San
Diego, CA). Statistically signiﬁcant differences were assessed by nonparametric two-side Mann–
Whitney U-test with 95% conﬁdence bounds. Signiﬁcance was accepted at Po0.05.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2016.02.040.References
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